Status:

COMPLETED

Evaluation of the Immediate Effect and Safety of DMA™ Novel Muscle Stimulation Technology

Lead Sponsor:

Lumenis Be Ltd.

Conditions:

Skin Laxity

Muscle Contracture

Eligibility:

All Genders

25-45 years

Phase:

NA

Brief Summary

A total of at least 15 and up to 17 healthy subjects at a single site, aged 25-45 years old, who wish to receive a lifting effect and improved muscle definition, will be included in the study. The pr...

Detailed Description

Single center, prospective, open Label with Before \& After Study Design. This study is designed to evaluate the immediate efficacy and safety of Legend Pro™'s DMA™ muscle stimulation technology. Trea...

Eligibility Criteria

Inclusion

  • Subject read, understood and signed the Consent Form
  • Healthy male or female aged 25-45 years,
  • Fitzpatrick skin type 1-6
  • Subject is capable of reading, understanding and following instructions of the procedure to be applied.
  • Subject is able and willing to comply with the treatment.
  • Women of child-bearing potential are required to use two forms of reliable methods of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, NuvaRing, partner with vasectomy, Implanon or other FDA-approved devices, or abstinence) during the course of the study.

Exclusion

  • General
  • Subject is female who is pregnant, lactating, or plans to become pregnant during the study period or had given birth less than 6 months ago.
  • Concurrent participation in any other study.
  • Specific to the treatment and treatment area
  • Subject has a pacemaker or internal defibrillator, implanted neurostimulators or any other internal electric device or patient who had an implant in the past.
  • Subject has metal or other implants in the treatment area (Not including dental fillings, implants and crowns).
  • Subject has significant concurrent skin conditions affecting areas to be treated such as sores, bleeding, skin fragility, eczema or psoriasis.
  • Subject has burned, blistered, irritated, or sensitive skin due to excessive fresh tanning in areas to be treated or is unlikely to refrain from excessive tanning during the study.
  • Other treatments
  • Subject has used oral isotretinoin (Accutane or Roaccutan®) within 6 months prior to study enrollment or plans use during the course of the study.
  • Subject has used topical retinoids in past 1 month
  • Medical conditions/ use of medication
  • Subject has current or history of systemic cancer; premalignant skin lesion or skin concern treatment area.
  • Subject has severe concurrent conditions such as epilepsy, autoimmune, pulmonary or cardiac disorders.
  • Subject has poorly controlled endocrine disorders such as diabetes.
  • Subject has an impaired immune system due to immunosuppressive diseases such as HIV or AIDS, or use of immunosuppressive medications.
  • Subject has history of collagen disorders, keloid formation or abnormal wound healing.
  • Subject takes or has taken medications, herbal preparations, food supplements or vitamins that might cause fragile skin or impaired skin healing
  • Subject has used oral steroids in past 6 months
  • Subject has used topical steroids in past 3 months
  • Subject has history of bleeding coagulopathies or use of anticoagulants.
  • Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g. ibuprofen containing agents) one week before and after each treatment session prior to treatment
  • Subject has mental disorders that in the opinion of the Investigator would be interfere with ability to comply with the study requirements.
  • Subject has any other medical condition that in the opinion of the Investigator warrants exclusion from this study

Key Trial Info

Start Date :

September 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 15 2021

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT04296201

Start Date

September 1 2020

End Date

February 15 2021

Last Update

February 17 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dermatology, Laser, and Vein Specialists of the Carolinas, PLLC

Charlotte, North Carolina, United States, 28207

Evaluation of the Immediate Effect and Safety of DMA™ Novel Muscle Stimulation Technology | DecenTrialz